Roquinimex
Wikipedia on Answers.com:
Top
Roquinimex
 |
|
|---|---|
| Systematic (IUPAC) name | |
| 4-hydroxy-N,1-dimethyl-2-oxo-N- phenyl-1,2-dihydroquinoline-3-carboxamide |
|
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Pharmacokinetic data | |
| Half-life | 26-42 hours |
| Identifiers | |
| CAS number | 84088-42-6  |
| ATC code | L03AX02 |
| PubChem | CID 55197 |
| UNII | 372T2944C0 |
| Chemical data | |
| Formula | C18H16N2O3 |
| Mol. mass | 308.331 g/mol |
 (what is this?) (verify) |
|
Roquinimex (Linomide) is a quinoline derivative immunostimulant which increases NK cell activity and macrophage cytotoxicity. It also inhibits angiogenesis and reduces the secretion of TNF alpha.
Roquinimex has been investigated as a treatment for some cancers (including as adjuvant therapy after bone marrow transplantation in acute leukemia) and autoimmune diseases, such as multiple sclerosis and recent-onset type I diabetes. Several trials have been terminated due to serious cardiovascular toxicity.
|
|||||||||||||||||||||||||||||
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
Post a question - any question - to the WikiAnswers community:
Copyrights:
Wikipedia on Answers.com
This article is licensed under the Creative Commons Attribution/Share-Alike License. It uses material from the Wikipedia article Roquinimex.
Read more